阅读说明：本技术 用于前列腺癌的治疗性rna (Therapeutic RNA for prostate cancer ) 是由 大卫·韦伯 卡里纳·韦尔特 戴安娜·巴雷亚罗尔丹 鲁普雷希特·库纳 叶利夫·迪肯 马丁·苏 于 2020-03-11 设计创作，主要内容包括：本文中公开了用于治疗前列腺癌的组合物、用途和方法。在一个方面中,本文中公开了包含至少一种RNA的组合物或药物制剂,其中所述至少一种RNA编码以下氨基酸序列：(i)包含激肽释放酶-2(KLK2)、其免疫原性变体、或者KLK2的免疫原性片段或其免疫原性变体的氨基酸序列；(ii)包含前列腺特异性抗原(PSA)、其免疫原性变体、或者PSA的免疫原性片段或其免疫原性变体的氨基酸序列；(iii)包含前列腺酸性磷酸酶(PAP)、其免疫原性变体、或者PAP的免疫原性片段或其免疫原性变体的氨基酸序列；(iv)包含同源框B13(HOXB13)、其免疫原性变体、或者HOXB13的免疫原性片段或其免疫原性变体的氨基酸序列；以及(v)包含NK3同源框1(NKX3-1)、其免疫原性变体、或者NKX3-1的免疫原性片段或其免疫原性变体的氨基酸序列。(Disclosed herein are compositions, uses and methods for treating prostate cancer. In one aspect, disclosed herein is a composition or pharmaceutical formulation comprising at least one RNA encoding the amino acid sequence: (i) an amino acid sequence comprising kallikrein-2 (KLK2), an immunogenic variant thereof, or an immunogenic fragment of KLK2 or an immunogenic variant thereof; (ii) an amino acid sequence comprising Prostate Specific Antigen (PSA), an immunogenic variant thereof, or an immunogenic fragment of PSA or an immunogenic variant thereof; (iii) an amino acid sequence comprising Prostatic Acid Phosphatase (PAP), an immunogenic variant thereof, or an immunogenic fragment of PAP or an immunogenic variant thereof; (iv) an amino acid sequence comprising homology box B13(HOXB13), an immunogenic variant thereof, or an immunogenic fragment of HOXB13 or an immunogenic variant thereof; and (v) an amino acid sequence comprising NK3 homeobox 1(NKX3-1), an immunogenic variant thereof, or an immunogenic fragment of NKX3-1 or an immunogenic variant thereof.)